Mechanistic insights of an immunological adverse event induced by an anti-KIT antibody drug conjugate and mitigation strategies.

CONCLUSIONS: Our data suggests LOP628-mediated mast cell degranulation is the likely cause of HSR observed in the clinic due to co-engagement of the FcγR and KIT, resulting in mast cell activation.
PMID: 29615457 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 3, 2018 Category: Cancer & Oncology Authors: L'Italien LE, Orozco O, Abrams TJ, Cantagallo L, Connor A, Desai J, Ebersbach H, Gelderblom H, Hoffmaster K, Lees E, Maacke H, Schleyer S, Skegro D, Lee-Hoeflich ST Tags: Clin Cancer Res Source Type: research